These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16028007)

  • 1. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S; Wientjes MG; Walsh C; Au JL
    Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
    Song S; Yu B; Wei Y; Wientjes MG; Au JL
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6058-65. PubMed ID: 15447990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft.
    Jia Y; Zhou D; Jia Q; Ying Y; Chen S
    Biomed Pharmacother; 2016 Apr; 79():27-34. PubMed ID: 27044809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
    Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
    Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
    Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
    Luke JJ; LoRusso P; Shapiro GI; Krivoshik A; Schuster R; Yamazaki T; Arai Y; Fakhoury A; Dmuchowski C; Infante JR
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):549-58. PubMed ID: 26811179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
    Miller VA; Kris MG
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.